| Autor: |
López-Muñoz AD; Cellular Biology Section, Laboratory of Viral Diseases, NIAID (NIH), Bethesda, Maryland, United States., Kosik I; Cellular Biology Section, Laboratory of Viral Diseases, NIAID (NIH), Bethesda, Maryland, United States., Holly J; Cellular Biology Section, Laboratory of Viral Diseases, NIAID (NIH), Bethesda, Maryland, United States., Yewdell JW; Cellular Biology Section, Laboratory of Viral Diseases, NIAID (NIH), Bethesda, Maryland, United States. |
| Abstrakt: |
SARS-CoV-2 nucleocapsid protein (N) induces strong antibody and T cell responses. Although considered to be localized in the cytosol, we readily detect N on the surface of live cells. N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans. N binds with high affinity to 11 human chemokines, including CXCL12β, whose chemotaxis of leukocytes is inhibited by N from SARS-CoV-2, SARS-CoV-1, and MERS CoV. Anti-N Abs bound to the surface of N expressing cells activate Fc receptor-expressing cells. Our findings indicate that cell surface N manipulates innate immunity by sequestering chemokines and can be targeted by Fc expressing innate immune cells. This, in combination with its conserved antigenicity among human CoVs, advances its candidacy for vaccines that induce cross-reactive B and T cell immunity to SARS-CoV-2 variants and other human CoVs, including novel zoonotic strains. |
